Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.210 USD | +2.16% |
|
-8.11% | -33.72% |
Feb. 10 | Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating | MT |
Feb. 06 | Alumis And Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company | RE |
Capitalization | 283M 270M 255M 225M 402M 24.56B 446M 3.03B 1.12B 10.27B 1.06B 1.04B 43.1B | P/E ratio 2024 * |
-0.6x | P/E ratio 2025 * | -1.31x |
---|---|---|---|---|---|
Enterprise value | 163M 155M 146M 129M 231M 14.11B 256M 1.74B 645M 5.9B 611M 598M 24.77B | EV / Sales 2024 * |
-
| EV / Sales 2025 * | - |
Free-Float |
85.75% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Alumis Inc.
1 day | +2.16% | ||
1 week | -8.11% | ||
Current month | -30.35% | ||
1 month | -31.81% | ||
3 months | -44.63% | ||
6 months | -59.01% | ||
Current year | -33.72% |







Director | Title | Age | Since |
---|---|---|---|
Martin Babler
CEO | Chief Executive Officer | 60 | 2021-09-22 |
John Schroer
DFI | Director of Finance/CFO | 60 | 2022-04-30 |
Roman Rubio
CTO | Chief Tech/Sci/R&D Officer | 54 | 2022-08-31 |
Manager | Title | Age | Since |
---|---|---|---|
James Tananbaum
BRD | Director/Board Member | 60 | 2021-04-30 |
Zheng Bin Yao
BRD | Director/Board Member | 59 | 2021-05-31 |
Martin Babler
CHM | Chairman | 60 | 2021-09-22 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+2.16% | -8.11% | - | - | 283M | ||
-0.77% | -2.20% | +9.84% | +98.50% | 118B | ||
-0.10% | -5.13% | -28.93% | +8.03% | 72.09B | ||
-2.13% | -3.83% | +68.23% | +140.90% | 38.79B | ||
-2.40% | +1.89% | +31.02% | -22.46% | 28.73B | ||
+2.38% | +3.29% | +58.26% | +12.45% | 24.63B | ||
+4.61% | +2.25% | +11.97% | -30.27% | 23.61B | ||
-2.06% | +6.27% | +380.22% | +952.71% | 15.76B | ||
+0.81% | -0.80% | +189.03% | +244.83% | 14.19B | ||
+0.94% | +8.59% | -19.89% | -31.61% | 13.46B | ||
Average | +0.34% | +0.15% | +77.75% | +152.57% | 34.94B | |
Weighted average by Cap. | -0.26% | -1.16% | +36.48% | +99.29% |
2024 * | 2025 * | |
---|---|---|
Net sales | - | - |
Net income | -276M -263M -248M -219M -392M -23.94B -434M -2.95B -1.09B -10.01B -1.04B -1.02B -42.02B | -298M -284M -268M -236M -422M -25.82B -469M -3.19B -1.18B -10.8B -1.12B -1.09B -45.33B |
Net Debt | -121M -115M -108M -95.62M -171M -10.45B -190M -1.29B -478M -4.37B -452M -443M -18.34B | 58.39M 55.59M 52.43M 46.31M 82.73M 5.06B 91.8M 624M 231M 2.12B 219M 214M 8.88B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 5.210 $ | +2.16% | 115,186 |
25-02-13 | 5.100 $ | +1.39% | 164,348 |
25-02-12 | 5.030 $ | +0.40% | 166,115 |
25-02-11 | 5.010 $ | +3.94% | 390,297 |
25-02-10 | 4.820 $ | -14.99% | 425,252 |
Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALMS Stock